UK markets closed
NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.45 -0.03 (-0.04%) GOLD FUTURES
2,322.10 -9.10 (-0.39%) DOW
38,868.65 +16.38 (+0.04%) Bitcoin GBP
50,373.61 -273.77 (-0.54%)
Innate Pharma S.A. (IPHA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:23PM EDT. Market open.
| Previous close | 2.4200 |
| Open | 2.4800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4800 - 2.5350 |
| 52-week range | 1.8100 - 3.5700 |
| Volume | |
| Avg. volume | 9,400 |
| Market cap | 204.934M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
MARSEILLE, France, May 07, 2024--Innate Pharma announces conference call and webcast for Q1 business update
- Business Wire
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
- Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024
© 2024 Yahoo. All rights reserved.